Global Evaluation News Today

Company Plans to Discontinue the Phase 3 Clinical Trial of Reldesemtiv After Data Monitoring Committee Found No Effect on Primary or Key Secondary Endpoints Cytokinetics to Host Conference Call and... | March 31, 2023

Introduction In this era of globalization, infectious disease transmission has become a matter of concern for public health safety. Human (...)

FinancialNewsMedia.com News Commentary PALM BEACH, Fla., June 22, 2022 /PRNewswire/ -- Neuroinflammatory disorder is the study of conditions where immune responses which damage components

/PRNewswire/ -- Neuroinflammatory disorder is the study of conditions where immune responses which damage components of the nervous system. It includes many...

Initial Data from REDWOOD-HCM OLE, the Open Label Extension Study of Aficamten, to be Presented at Heart Failure 2022 on May 23, 2022 Continued Launch...

[supply concerns lead to "demon nickel" haunting related listed companies into "golden branch jade nickel"] supply concerns triggered a sharp rise in nickel prices on the 7th, while the main contract of Shanghai nickel also closed by the daily limit. Greenmei said that by 2025, the company's Indonesian nickel resources project nickel metal production capacity will exceed 100000 metal tons / year, the benefits will be fully released, and actively promote the construction ...

July 16, 2021 LAHORE: As several studies spotlight the intersection of the HIV and COVID-19 pandemics, new evidence from a large-scale World Health Organization (WHO) analysis reveals that HIV is a significant independent risk factor for severe COVID-19 illness at hospitalization and in-hospital death. IAS – International AIDS Society – calls upon all countries for people living with HIV to be included in priority populations for COVID-19 vaccine rollout. The studies highlighting new evide...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Cytokinetics Announces Data and Trial Design Presented at the International Symposium on ALS/MND Cytokinetics, IncorporatedDecember 14, 2020 GMT SOUTH SAN FRANCISCO, Calif., Dec. 14, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that additional data relating to the impact of patient characteristics on treatment effect in FORTITUDE-ALS, the Phase 2 clinical trial o...